Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Forest/Paion’s Desmoteplase Program In Question After Failed Stroke Trial

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Companies announce a Phase III study in acute ischemic stroke patients failed to show an efficacy benefit over placebo.

You may also be interested in...



H. Lundbeck Adds North American Rights To Desmoteplase In Revised Deal With Paion

Danish firm plans a new Phase III trial for the second half of 2008 based on reanalysis of data from failed studies of the clot-busting agent.

H. Lundbeck Adds North American Rights To Desmoteplase In Revised Deal With Paion

Danish firm plans a new Phase III trial for the second half of 2008 based on reanalysis of data from failed studies of the clot-busting agent.

Forest Terminates Desmoteplase Co-Development Deal With Paion

The action comes after the clot-dissolving protein failed to show a treatment benefit in acute ischemic stroke patients.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS066155

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By